

Ashley B. Irish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6978022/publications.pdf>

Version: 2024-02-01

150
papers

4,297
citations

109321

35
h-index

123424

61
g-index

151
all docs

151
docs citations

151
times ranked

5668
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. <i>Journal of Vascular Access</i> , 2024, 25, 193-202.	0.9	2
2	The extrapyramidal syndromes of chronic kidney disease and dialysis (EPS-CKDD): diagnostic criteria, risk factors and prognosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 359-366.	0.5	6
3	Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A pre-specified cross-sectional study of the FAVOURED trial participants. <i>Journal of Human Nutrition and Dietetics</i> , 2022, 35, 1178-1191.	2.5	0
4	mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients. <i>Frontiers in Medicine</i> , 2022, 9, 722058.	2.6	1
5	Which NK cell populations mark the high burden of CMV present in all HIV patients beginning ART in Indonesia?. <i>AIDS Research and Therapy</i> , 2022, 19, 16.	1.7	2
6	The effect of radiological imaging on treatment delay and hospitalisation in patients with peritoneal dialysis-related peritonitis: A secondary analysis of the PROMPT study. <i>Peritoneal Dialysis International</i> , 2022, 42, 154-161.	2.3	2
7	Sequencing of the Viral UL111a Gene Directly from Clinical Specimens Reveals Variants of HCMV-Encoded IL-10 That Are Associated with Altered Immune Responses to HCMV. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4644.	4.1	3
8	A TNF Block Genotype may Influence CMV Retinitis in HIV Patients without Affecting Systemic Viral Replication. <i>Current HIV Research</i> , 2021, 19, 96-99.	0.5	1
9	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. <i>Kidney360</i> , 2021, 2, 674-683.	2.1	2
10	Understanding the effects of CMV on $\hat{3}$ T-cell populations in HIV patients starting antiretroviral therapy. <i>Clinical Immunology</i> , 2021, 226, 108696.	3.2	2
11	Neurocognitive outcomes in Indonesians living with HIV are influenced by polymorphisms in the gene encoding purinergic P2X receptor 7. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 13, 100220.	2.5	1
12	Immunohistochemical evidence of P2X7R, P2X4R and CaMKK2 in pyramidal neurons of frontal cortex does not align with Alzheimer's disease. <i>Experimental and Molecular Pathology</i> , 2021, 120, 104636.	2.1	4
13	Nephritis and Hearing Loss – Not All Roads Lead to Alport Syndrome. <i>Kidney International Reports</i> , 2021, 6, 2922-2925.	0.8	0
14	Polymorphisms in CAMKK2 may influence domain-specific neurocognitive function in HIV+ Indonesians receiving ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 115-119.	2.1	0
15	Sequencing Directly from Clinical Specimens Reveals Genetic Variations in HCMV-Encoded Chemokine Receptor US28 That May Influence Antibody Levels and Interactions with Human Chemokines. <i>Microbiology Spectrum</i> , 2021, 9, e0002021.	3.0	4
16	Challenging the Conventional Interpretation of HCMV Seronegativity. <i>Microorganisms</i> , 2021, 9, 2382.	3.6	2
17	Cytomegalovirus may influence vascular endothelial health in Indonesian HIV-infected patients after 5 years on ART. <i>AIDS Research and Therapy</i> , 2021, 18, 83.	1.7	1
18	Determinants of cognitive health in Indonesian HIV patients beginning antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2020, 26, 32-40.	2.1	12

#	ARTICLE	IF	CITATIONS
19	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 657-668.	0.7	22
20	Allograft and Patient Outcomes Between Indigenous and Nonindigenous Kidney Transplant Recipients. <i>Transplantation</i> , 2020, 104, 847-855.	1.0	7
21	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. <i>Kidney360</i> , 2020, 1, 1259-1269.	2.1	8
22	P152â€¦Epidemiology and practice patterns in the management of lupus nephritis in Australia. , 2020, , .		0
23	Periodontitis and Cytomegalovirus Associate With Atherosclerosis Among HIV Patients After 5 Years on ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 195-200.	2.1	3
24	Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients. <i>Non-coding RNA</i> , 2020, 6, 50.	2.6	6
25	The role of CAMKK2 polymorphisms in HIV-associated sensory neuropathy in South Africans. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116987.	0.6	7
26	TNF-Block Genotypes Influence Susceptibility to HIV-Associated Sensory Neuropathy in Indonesians and South Africans. <i>International Journal of Molecular Sciences</i> , 2020, 21, 380.	4.1	3
27	Cytomegalovirus burden improves a predictive model identifying measures of vascular risk in renal transplant recipients and healthy adults. <i>Journal of Medical Virology</i> , 2020, 92, 3650-3657.	5.0	7
28	Polymorphisms in CAMKK2 associate with susceptibility to sensory neuropathy in HIV patients treated without stavudine. <i>Journal of NeuroVirology</i> , 2019, 25, 814-824.	2.1	8
29	The Detection of CMV in Saliva Can Mark a Systemic Infection with CMV in Renal Transplant Recipients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5230.	4.1	12
30	Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients. <i>Viral Immunology</i> , 2019, 32, 355-360.	1.3	2
31	Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. <i>Transplantation Direct</i> , 2019, 5, e416.	1.6	56
32	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. <i>PLoS ONE</i> , 2019, 14, e0213274.	2.5	8
33	Immunogenicity and protective potential of <i>Bordetella pertussis</i> biofilm and its associated antigens in a murine model. <i>Cellular Immunology</i> , 2019, 337, 42-47.	3.0	9
34	A high burden of cytomegalovirus marks poor vascular health in transplant recipients more clearly than in the general population. <i>Clinical and Translational Immunology</i> , 2019, 8, e1043.	3.8	16
35	The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients. , 2019, 29, 377-385.		6
36	Characterization of Natural Killer Cells in HIV Patients Beginning Therapy with a High Burden of Cytomegalovirus. <i>Immunological Investigations</i> , 2019, 48, 345-354.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Functional and clinical consequences of changes to natural killer cell phenotypes driven by chronic cytomegalovirus infections. <i>Journal of Medical Virology</i> , 2019, 91, 1120-1127.	5.0	8
38	P6244 Cytomegalovirus (CMV) burden may be used to enhance algorithms to predict future cardiovascular health in renal transplant recipients and healthy controls. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
39	Omega-3 Polyunsaturated Fatty Acid Supplementation to Prevent Arteriovenous Fistula and Graft Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2018, 72, 50-61.	1.9	13
40	The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 136, 1-8.	1.9	41
41	The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. <i>Seminars in Dialysis</i> , 2018, 31, 244-257.	1.3	45
42	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 71, 382-391.	1.9	41
43	HIV patients, healthy aging and transplant recipients can reveal the hidden footprints of CMV. <i>Clinical Immunology</i> , 2018, 187, 107-112.	3.2	11
44	Comparison of the Incidence, Risk Factors and Types of Acute Rejection between Indigenous and Non-Indigenous Australians with Kidney Transplants. <i>Transplantation</i> , 2018, 102, S324.	1.0	0
45	FP55 EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i227-i227.	0.7	2
46	Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963-2013. <i>Nephrology</i> , 2018, 23, 217-225.	1.6	6
47	Correlation and agreement between eplet mismatches calculated using serological, low-intermediate and high resolution molecular human leukocyte antigen typing methods. <i>Oncotarget</i> , 2018, 9, 13116-13124.	1.8	12
48	Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfv326.	0.7	14
49	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. <i>Nephrology</i> , 2017, 22, 823-824.	1.6	3
50	Cytomegalovirus antibody and vascular pathology in renal transplant recipients. <i>Journal of Medical Virology</i> , 2017, 89, 177-181.	5.0	18
51	Cytomegalovirus infection alters phenotypes of different T cell subsets in renal transplant recipients with long-term stable graft function. <i>Journal of Medical Virology</i> , 2017, 89, 1442-1452.	5.0	20
52	Infectious complications in indigenous renal transplant recipients in Western Australia. <i>Internal Medicine Journal</i> , 2017, 47, 648-655.	0.8	11
53	CMV drives the expansion of highly functional memory T cells expressing NK cell receptors in renal transplant recipients. <i>European Journal of Immunology</i> , 2017, 47, 1324-1334.	2.9	27
54	The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy. <i>Clinical Immunology</i> , 2017, 179, 54-63.	3.2	1

#	ARTICLE	IF	CITATIONS
55	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2017, 177, 184.	5.1	77
56	The effect of genetic variants affecting NK cell function on cardiovascular health and the burden of CMV. <i>Human Immunology</i> , 2017, 78, 747-751.	2.4	8
57	Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial. <i>Clinical Transplantation</i> , 2017, 31, e13043.	1.6	1
58	Persistence of Activated and Adaptive-Like NK Cells in HIV+ Individuals despite 2 Years of Suppressive Combination Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2017, 8, 731.	4.8	24
59	Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART. <i>AIDS Research and Therapy</i> , 2017, 14, 52.	1.7	18
60	n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2016, 8, 175.	4.1	32
61	Baseline characteristics of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in Renal Disease (FAVOURED) study. <i>Nephrology</i> , 2016, 21, 217-228.	1.6	10
62	Graft nephrectomy for people with a failed kidney transplant. <i>The Cochrane Library</i> , 2016, , .	2.8	0
63	Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy. <i>BMC Infectious Diseases</i> , 2016, 16, 342.	2.9	35
64	The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study. <i>Kidney International Reports</i> , 2016, 1, 65-72.	0.8	37
65	Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcR1 ⁺ NK cells. <i>European Journal of Immunology</i> , 2016, 46, 2597-2608.	2.9	20
66	Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?. <i>Journal of Clinical Immunology</i> , 2016, 36, 113-116.	3.8	8
67	A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. <i>Clinical Nutrition</i> , 2016, 35, 331-336.	5.0	55
68	The immunological footprint of CMV in HIV-1 patients stable on long-term ART. <i>Immunity and Ageing</i> , 2015, 12, 14.	4.2	15
69	n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease. <i>Journal of Hypertension</i> , 2015, 33, 1947-1953.	0.5	23
70	An NK Cell Population Lacking FcR1 ⁺ Is Expanded in Chronically Infected HIV Patients. <i>Journal of Immunology</i> , 2015, 194, 4688-4697.	0.8	70
71	When Thoracic Organ Recipients Become Abdominal Organ Donors: Sharing the Risks and Benefits of Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2015, 47, 201-203.	0.6	1
72	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. <i>BMC Nephrology</i> , 2015, 16, 89.	1.8	21

#	ARTICLE	IF	CITATIONS
73	A case of iatrogenic cushing syndrome and apparent mineralocorticoid excess presenting with accelerated hypertension and proteinuria. Internal Medicine Journal, 2014, 44, 932-934.	0.8	1
74	A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 2014, 11, 35.	1.7	16
75	Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy. Clinical Immunology, 2014, 155, 149-159.	3.2	10
76	Modeling the Benefits and Costs of Integrating an Acceptable HLA Mismatch Allocation Model for Highly Sensitized Patients. Transplantation, 2014, 97, 769-774.	1.0	20
77	Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. International Urology and Nephrology, 2013, 45, 795-802.	1.4	31
78	Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. Transplant Immunology, 2013, 29, 22-27.	1.2	36
79	Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transplant Immunology, 2013, 28, 148-153.	1.2	52
80	Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology, 2013, 18, 63-70.	1.6	5
81	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	27.0	844
82	Insulin Resistance and the Metabolic Syndrome Are Associated With Arterial Stiffness in Patients With Chronic Kidney Disease. American Journal of Hypertension, 2013, 26, 1155-1161.	2.0	22
83	178 20-HETE CONTRIBUTES TO THE BLOOD PRESSURE REDUCTION FOLLOWING OMEGA-3 FATTY ACID SUPPLEMENTATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Hypertension, 2012, 30, e54.	0.5	0
84	Third-Party Red-Cell Transfusion in the First 30 Days after Renal Transplantation in Patients with Donor Specific Antibodies Is Associated with Antibody-Mediated Rejection. Transplantation, 2012, 94, 180.	1.0	0
85	Dysproteinemias or light chain diseases. , 2012, , 251-264.		1
86	Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus-infected patients?. Human Immunology, 2012, 73, 168-174.	2.4	8
87	Acute irreversible oxalate nephropathy in a lung transplant recipient treated successfully with a renal transplant. Nephrology, 2012, 17, 12-15.	1.6	5
88	Incidence, risk factors and prognosis of acute kidney injury after transcatheter aortic valve implantation. Nephrology, 2012, 17, 445-451.	1.6	48
89	Lupus mastitis: a mimicker of breast carcinoma. BMJ Case Reports, 2011, 2011, bcr1120115066-bcr1120115066.	0.5	13
90	Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 3543-3549.	0.7	26

#	ARTICLE	IF	CITATIONS
91	Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. <i>Journal of Lipid Research</i> , 2011, 52, 794-800.	4.2	53
92	Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. <i>Nephrology</i> , 2010, 15, 714-719.	1.6	4
93	Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 920-926.	0.7	13
94	Myeloma and the Kidney. , 2010, , 761-769.		2
95	Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. <i>American Heart Journal</i> , 2010, 160, 785-794.e10.	2.7	257
96	Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1828-1833.	0.7	13
97	Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. <i>Journal of Lipid Research</i> , 2009, 50, 2524-2531.	4.2	62
98	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) study. <i>BMC Nephrology</i> , 2009, 10, 1.	1.8	58
99	The effects of ω 3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. <i>Journal of Hypertension</i> , 2009, 27, 1863-1872.	0.5	87
100	Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. <i>Thrombosis Research</i> , 2008, 123, 374-380.	1.7	78
101	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. <i>Atherosclerosis</i> , 2008, 196, 823-834.	0.8	57
102	Post-Transplant HLA class II Antibodies and High Soluble CD30 Levels are Independently Associated with Poor Kidney Graft Survival. <i>American Journal of Transplantation</i> , 2007, 7, 847-856.	4.7	64
103	Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. <i>American Journal of Kidney Diseases</i> , 2007, 49, 301-309.	1.9	62
104	A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 49, 776-785.	1.9	49
105	Insulin Resistance, Inflammation, and Blood Pressure Determine Vascular Dysfunction in CKD. <i>American Journal of Kidney Diseases</i> , 2006, 48, 926-934.	1.9	74
106	Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 234-235.	0.7	22
107	HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study. <i>Clinical Transplants</i> , 2006, , 219-25.	0.2	1
108	HLA donor-specific antibody detected by solid phase assay identifies high-risk transplantation pairs irrespective of CDC crossmatch results: case reports and literature review. <i>Clinical Transplants</i> , 2006, , 497-501.	0.2	1

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. <i>Nephrology</i> , 2005, 10, 336-340.	1.6	34
110	A Review of the Current Treatment of Renal Artery Stenosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 29, 479-488.	1.5	22
111	Diagnostic challenges associated with a complex case of cystic pheochromocytoma presenting with malignant hypertension, microangiopathic haemolysis and acute renal failure. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1014-1014.	0.7	8
112	Foreword from the organisers. <i>Nephrology</i> , 2004, 9, S107-S108.	1.6	0
113	Hypercoagulability in Renal Transplant Recipients. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 139-149.	2.2	80
114	A prisoner with acute renal failure. <i>Lancet, The</i> , 2004, 363, 126.	13.7	2
115	Recommendations for the use of icodextrin in peritoneal dialysis patients. Review Article. <i>Nephrology</i> , 2003, 8, 1-7.	1.6	36
116	Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2220-2225.	0.7	45
117	Prevention of Tunneled Hemodialysis Catheter-Related Infections Using Catheter-Restricted Filling with Gentamicin and Citrate. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2133-2139.	6.1	255
118	Statin therapy improves brachial artery endothelial function in nephrotic syndrome. <i>Kidney International</i> , 2002, 62, 550-557.	5.2	45
119	PREVENTION OF TUNNELED HAEMODIALYSIS CATHETER (TC) RELATED INFECTIONS USING CATHETER RESTRICTED FILLING WITH GENTAMICIN AND CITRATE. <i>Nephrology</i> , 2002, 7, A54-A54.	1.6	6
120	How hot is homocysteine?. <i>Nephrology</i> , 2002, 7, S56-S57.	1.6	0
121	How hot is homocysteine?. <i>Nephrology</i> , 2002, 7, S56-S57.	1.6	0
122	Homocysteine and nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1720-1721.	0.7	9
123	Vascular function of the peripheral circulation in patients with nephrosis. <i>Kidney International</i> , 2001, 60, 182-189.	5.2	37
124	Oxidant stress in nephrotic syndrome: comparison of F ₂ -isoprostanes and plasma antioxidant potential. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1626-1630.	0.7	36
125	Renal allograft thrombosis: can thrombophilia explain the inexplicable?. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2297-2303.	0.7	34
126	Cardiovascular disease, fibrinogen and the acute phase response Associations with lipids and blood pressure in patients with chronic renal disease. <i>Atherosclerosis</i> , 1998, 137, 133-139.	0.8	107

#	ARTICLE	IF	CITATIONS
127	Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 679-684.	0.7	40
128	The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 1680-1683.	0.7	14
129	Presentation and survival of patients with severe renal failure and myeloma. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 773-780.	0.5	59
130	Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 167-173.	0.7	53
131	Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 36-40.	3.4	29
132	Intracellular Free Magnesium Concentrations in Skeletal Muscle in Chronic Uraemia. <i>Nephron</i> , 1997, 76, 20-25.	0.6	7
133	Chronic renal disease and cardiovascular complications: inevitable or preventable? Now is the time for some intervention studies. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 273-274.	0.5	0
134	THE FACTOR V LEIDEN (R506Q) MUTATION AND RISK OF THROMBOSIS IN RENAL TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1997, 64, 604-607.	1.0	62
135	The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure. <i>Clinical Nephrology</i> , 1997, 47, 372-8.	0.7	16
136	Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. <i>Kidney International</i> , 1996, 50, 282-289.	5.2	56
137	The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 2223-2228.	0.7	17
138	Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. <i>Clinical Nephrology</i> , 1996, 45, 386-9.	0.7	6
139	Aerobic and Anaerobic ATP Synthesis in Exercising Muscle of Patients with Chronic Renal Failure (CRF). <i>Clinical Science</i> , 1995, 89, 27P-27P.	0.0	0
140	Cyclosporin and serum lipids in renal transplant recipients. <i>Lancet, The</i> , 1993, 341, 765-767.	13.7	31
141	Cyclosporin and serum lipids in renal transplant recipients. <i>Lancet, The</i> , 1993, 341, 766; author reply 767.	13.7	0
142	Supplementing renal function with CAPD in a patient with chronic renal failure and pregnancy. <i>Peritoneal Dialysis International</i> , 1993, 13, 155-6.	2.3	3
143	Late presentation and development of nephrocalcinosis in primary hyperoxaluria. <i>Australian and New Zealand Journal of Medicine</i> , 1992, 22, 48-50.	0.5	4
144	Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1992, 22, 243-248.	0.5	53

#	ARTICLE	IF	CITATIONS
145	Lipoprotein(a) concentration in diabetes: relationship to proteinuria and diabetes control. Australian and New Zealand Journal of Medicine, 1992, 22, 329-333.	0.5	13
146	Simultaneous Presentation of Gastric Carcinoma and Crescentic Glomerulonephritis. Nephron, 1992, 60, 254-254.	1.8	4
147	Heat stroke following Rugby League football. Medical Journal of Australia, 1991, 155, 636-639.	1.7	19
148	Levels of CMV-reactive antibodies correlate with the induction of CD28null T cells and systemic inflammation in chronic obstructive pulmonary disease (COPD). Cellular and Molecular Immunology, 0, , .	10.5	3
149	Graft nephrectomy for people with a failed kidney transplant. The Cochrane Library, 0, , .	2.8	0
150	Î³Î³ T-cell subpopulations associate with recovery of memory function in Indonesian HIV patients starting ART. AIDS Research and Human Retroviruses, 0, , .	1.1	0